Monitored issues related to the regulation of laboratory developed tests and the VALID Act. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019. Monitored implementation of P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to P.L. 115-271, The SUPPORT Act; monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021.
Duration: December 1, 2016
to
December 31, 2020
General Issues: Health Issues , Medicare/Medicaid , Veterans , Budget/Appropriations
Spending: about $940,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), Office of Management & Budget (OMB), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stacey Hughes U.S. Senate Budget Cmte, Dpty Staff Dir;Ofce of the Asst. Maj. Ldr (Sen. Nickles), Policy Adv; Office of the Asst. Min. Ldr (Sen. Nickles), Policy Adv.;Senate Spec. Cmte on Aging (Sen.Cohen),Prof. Staff Member; U.S.Sen Connie Mack, Leg Asst/Schdlr
Mary Beth Savary Taylor Joint Economic Committee, General Counsel; U.S. Senator Connie Mack, Legislative Assistant
Katherine Raab House Cmte on Energy and Commerce, Prof. Staff; Congressman Mary Bono, Leg. Asst.; Congressman Elton Gallegly, Leg. Asst.; Congressman Michael Bilirakis, Leg. Asst.; Congressman Michael Bilirakis, Leg. Corr.; Congressman Michael Bilirakis, Staff Asst
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2020
THE NICKLES GROUP, LLC terminated an engagement in which they represented Guardant Health on Jan. 20, 2021.
Original Filing: 301241402.xml
Lobbying Issues
Monitored issues related to the regulation of laboratory developed tests and the VALID Act. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019. Monitored implementation of P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to P.L. 115-271, The SUPPORT Act; monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301213036.xml
Lobbying Issues
Monitored issues related to the regulation of laboratory developed tests and the VALID Act; issues related to liquid biopsy; S. 1895, Lower Health Care Costs Act of 2019; H.R. 861, End Surprise Billing Act of 2019. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to P.L. 115-271, The SUPPORT Act; H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act, related to COVID testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
2nd Quarter, 2020
In Q2, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $50,000. The report was filed on July 17, 2020.
Original Filing: 301190896.xml
Lobbying Issues
Monitored issues related to the regulation of laboratory developed tests and the VALID Act; issues related to liquid biopsy; S. 1895, Lower Health Care Costs Act of 2019; H.R. 861, End Surprise Billing Act of 2019. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to P.L. 115-271, The SUPPORT Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
1st Quarter, 2020
In Q1, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301171179.xml
Lobbying Issues
Monitored issues related to the regulation of laboratory developed tests and the VALID Act; issues related to liquid biopsy; S. 1895, Lower Health Care Costs Act of 2019; H.R. 861, End Surprise Billing Act of 2019. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). Issues related to P.L. 115-271, The SUPPORT Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
4th Quarter, 2019
In Q4, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124863.xml
Lobbying Issues
Monitored issues related to the regulation of laboratory developed tests and the VALID Act; issues related to liquid biopsy; S. 1895, Lower Health Care Costs Act of 2019; H.R. 861, End Surprise Billing Act of 2019. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the national coverage decision on lab developed tests; issues related to the 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
3rd Quarter, 2019
In Q3, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301075938.xml
Lobbying Issues
Monitored issues related to the regulation of laboratory developed tests and the VALID Act; issues related to liquid biopsy; S. 1895, Lower Health Care Costs Act of 2019; H.R. 861, End Surprise Billing Act of 2019. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the national coverage decision on lab developed tests; issues related to the 2020 Hospital Outpatient Prospective Payment proposed rule and the Laboratory Date of Service Policy.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
2nd Quarter, 2019
In Q2, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301055604.xml
Lobbying Issues
Issues related to the regulation of laboratory developed tests and the VALID Act; monitored issues related to drug pricing; issues related to liquid biopsy; S. 1895, Lower Health Care Costs Act of 2019; H.R. 861, End Surprise Billing Act of 2019. Monitored H.R. 1765, Donald Payne Sr. Colorectal Cancer Detection Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to liquid biopsy and precision medicine.
Agencies Lobbied
Veterans Affairs - Dept of (VA)
Lobbying Issues
Issues related to the national coverage decision on lab developed tests.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
1st Quarter, 2019
In Q1, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on April 17, 2019.
Original Filing: 301027954.xml
Lobbying Issues
Issues related to the regulation of laboratory developed tests and the VALID Act; monitored issues related to drug pricing; issues related to liquid biopsy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to liquid biopsy and precision medicine.
Agencies Lobbied
Veterans Affairs - Dept of (VA)
4th Quarter, 2018
In Q4, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on Jan. 18, 2019.
Original Filing: 301008043.xml
Lobbying Issues
Issues related to the regulation of laboratory developed tests and the VALID Act; monitored issues related to drug pricing; issues related to liquid biopsy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to liquid biopsy and precision medicine.
Agencies Lobbied
Veterans Affairs - Dept of (VA)
Lobbying Issues
Monitored H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act and Continuing Appropriations Act. Monitored H.R. 695, Further Additional Continuing Appropriations Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on Oct. 18, 2018.
Original Filing: 300989783.xml
Lobbying Issues
Issues related to regulation of diagnostics; monitored issues related to drug pricing.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300973234.xml
Lobbying Issues
Issues related to regulation of diagnostics.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300955812.xml
Lobbying Issues
Issues related to regulation of diagnostics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Medicare NCD on Next Gen Sequencing laboratory developed tests.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300937245.xml
Lobbying Issues
Issues related to LDT's; issues related to liquid biopsies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare reimbursement for laboratory tests.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300913018.xml
Lobbying Issues
Monitored issues related to LDT's; issues related to liquid biopsies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare reimbursement for laboratory tests and the 14 day rule.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on July 19, 2017.
Original Filing: 300891518.xml
Lobbying Issues
Monitored issues related to LDT's; monitored H.R. 1628, the American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare reimbursement for laboratory tests.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300873363.xml
Lobbying Issues
Monitored issues related to LDT's; monitored H.R. 1628, the American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare reimbursement for laboratory tests.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, THE NICKLES GROUP, LLC lobbied for Guardant Health , earning $20,000. The report was filed on Jan. 18, 2017.
Original Filing: 300849379.xml
Lobbying Issues
Monitored issues related to H.R. 34, The 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...